Polyoma BK virus-associated nephropathy in kidney-transplant patients: Effects of leflunomide on T-cell functions and disease outcome

International Immunopharmacology

Volumn 9, Issue 9, 2009, Pages 1131-1136

  Canivet, Cindy ^a   Rostaing, Lionel ^b,c   Galvani, Sylvain ^a   Böhler, Torsten ^a   Gandia, Peggy ^c   Mengelle, Catherine ^c   Guilbeau Frugier, Céline ^b   Thomsen, Mogens ^a   Salvayre, Robert ^a   Negre Salvayre, Anne ^a   Kamar, Nassim ^a,b  

^a INSERM   (France)

^b CHU RANGUEIL   (France)

^c CHU PURPAN   (France)

Author keywords

BK virus nephropathy; Flow cytometry; Kidney transplantation; Leflunomide; T cell function

Indexed keywords

BASILIXIMAB; BELATACEPT; BIOLOGICAL MARKER; CD71 ANTIGEN; CYCLOSPORIN A; ERYTHROPOIETIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; ASSAY; BK VIRUS; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL PARAMETERS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIGENS, CD; BK VIRUS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; ISOXAZOLES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEPHRITIS; POLYOMAVIRUS INFECTIONS; RECEPTORS, TRANSFERRIN; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649387968     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.05.004     Document Type: Article

References (42)

1. Gardner S.D., Field A.M., Coleman D.V., and Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1 7712 (Jun 19 1971) 1253-1257
2. Coleman D.V., Mackenzie E.F., Gardner S.D., Poulding J.M., Amer B., and Russell W.J. Human polyomavirus (BK) infection and ureteric stenosis in renal allograft recipients. J Clin Pathol 31 4 (Apr 1978) 338-347
3. Binet I., Nickeleit V., Hirsch H.H., Prince O., Dalquen P., Gudat F., et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 67 6 (Mar 27 1999) 918-922
4. Nickeleit V., Hirsch H.H., Binet I.F., Gudat F., Prince O., Dalquen P., et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol 10 5 (May 1999) 1080-1089
5. Hirsch H.H., Knowles W., Dickenmann M., Passweg J., Klimkait T., Mihatsch M.J., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347 7 (Aug 15 2002) 488-496
6. Ramos E., Drachenberg C.B., Papadimitriou J.C., Hamze O., Fink J.C., Klassen D.K., et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 13 8 (Aug 2002) 2145-2151
7. Randhawa P.S., Finkelstein S., Scantlebury V., Shapiro R., Vivas C., Jordan M., et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67 1 (Jan 15 1999) 103-109
8. Hirsch H.H., Brennan D.C., Drachenberg C.B., Ginevri F., Gordon J., Limaye A.P., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79 10 (May 27 2005) 1277-1286
9. Almeras C., Foulongne V., Garrigue V., Szwarc I., Vetromile F., Segondy M., et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 85 8 (Apr 27 2008) 1099-1104
10. Cherwinski H.M., Cohn R.G., Cheung P., Webster D.J., Xu Y.Z., Caulfield J.P., et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 275 2 (Nov 1995) 1043-1049
11. Davis J.P., Cain G.A., Pitts W.J., Magolda R.L., and Copeland R.A. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35 4 (Jan 30 1996) 1270-1273
12. Williams J.W., Mital D., Chong A., Kottayil A., Millis M., Longstreth J., et al. Experiences with leflunomide in solid organ transplantation. Transplantation 73 3 (Feb 15 2002) 358-366
13. Vanrenterghem Y., van Hooff J.P., Klinger M., Wlodarczyk Z., Squifflet J.P., Mourad G., et al. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation 78 1 (Jul 15 2004) 9-14
14. Farasati N.A., Shapiro R., Vats A., and Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 79 1 (Jan 15 2005) 116-118
15. Waldman W.J., Knight D.A., Blinder L., Shen J., Lurain N.S., Miller D.M., et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 42 5-6 (1999) 412-418
16. Chong A.S., Zeng H., Knight D.A., Shen J., Meister G.T., Williams J.W., et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transpl 6 1 (Jan 2006) 69-75
17. Josephson M.A., Gillen D., Javaid B., Kadambi P., Meehan S., Foster P., et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 81 5 (Mar 15 2006) 704-710
18. Faguer S., Hirsch H.H., Kamar N., Guilbeau-Frugier C., Ribes D., Guitard J., et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 20 11 (Nov 2007) 962-969
19. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., et al. Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 17 12 (Dec 2000) 1551-1557
20. Bohler T., Nolting J., Kamar N., Gurragchaa P., Reisener K., Glander P., et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit 29 1 (Feb 2007) 77-86
21. Bonvoisin C., Weekers L., Xhignesse P., Grosch S., Milicevic M., and Krzesinski J.M. Polyomavirus in renal transplantation: a hot problem. Transplantation 85 7 Suppl (Apr 15 2008) S42-S48
22. Leca N., Muczynski K.A., Jefferson J.A., de Boer I.H., Kowalewska J., Kendrick E.A., et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol 3 3 (May 2008) 829-835
23. Kadambi P.V., Josephson M.A., Williams J., Corey L., Jerome K.R., Meehan S.M., et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transpl 3 2 (Feb 2003) 186-191
24. Vats A., Shapiro R., Singh Randhawa P., Scantlebury V., Tuzuner A., Saxena M., et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75 1 (Jan 15 2003) 105-112
25. Kuypers D.R., Vandooren A.K., Lerut E., Evenepoel P., Claes K., Snoeck R., et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transpl 5 8 (Aug 2005) 1997-2004
26. Nickeleit V., Hirsch H.H., Zeiler M., Gudat F., Prince O., Thiel G., et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 15 3 (Mar 2000) 324-332
27. Sener A., House A.A., Jevnikar A.M., Boudville N., McAlister V.C., Muirhead N., et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 81 1 (Jan 15 2006) 117-120
28. Izzedine H., Launay-Vacher V., and Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 5 (May 2005) 804-817
29. Gummert J.F., Barten M.J., Sherwood S.W., van Gelder T., and Morris R.E. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther 291 3 (Dec 1999) 1100-1112
30. Barten M.J., van Gelder T., Gummert J.F., Boeke K., Shorthouse R., Billingham M.E., et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transpl 2 8 (Sep 2002) 719-732
31. Klupp J., van Gelder T., Dambrin C., Regieli J.J., Boeke K., Billingham M.E., et al. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection. J Heart Lung Transplant 23 3 (Mar 2004) 334-351
32. Gummert J.F., Barten M.J., van Gelder T., Billingham M.E., and Morris R.E. Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Transplantation 70 7 (Oct 15 2000) 1038-1049
33. Sankatsing S.U., Prins J.M., Yong S.L., Roelofsen J., van Kuilenburg A.B., Kewn S., et al. Mycophenolate mofetil inhibits T-cell proliferation in kidney transplant recipients without lowering intracellular dGTP and GTP. Transpl Int 21 11 (Nov 2008) 1066-1071
34. Kamar N., Glander P., Nolting J., Böhler T., Hambach P., Liefeldt L., Rostaing L., Neumayer H.H., and Budde K. Pharmacodynamic evaluation of the first dose of mycophenolate mofetil in patients before kidney transplantation. Clin J Am Soc Nephrol 4 5 (2009) 936-942
35. Ruckemann K., Fairbanks L.D., Carrey E.A., Hawrylowicz C.M., Richards D.F., Kirschbaum B., et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 273 34 (Aug 21 1998) 21682-21691
36. Birsan T., Dambrin C., Klupp J., Stalder M., Larson M.J., Fitzsimmons W.E., et al. In vivo pharmacokinetic and pharmacodynamic evaluation of the malononitrilamide FK778 in non-human primates. Transpl Int 16 5 (May 2003) 354-360
37. Birsan T., Dambrin C., Klupp J., Stalder M., Fitzsimmons W.E., and Morris R.E. Effects of the malononitrilamide FK778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. Transpl Immunol 11 2 (Apr-Jun 2003) 163-167
38. Clipstone N.A., and Crabtree G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357 6380 (Jun 25 1992) 695-697
39. Slauson S.D., Silva H.T., Sherwood S.W., and Morris R.E. Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol lett 67 3 (Apr 15 1999) 179-183
40. Knight D.A., Hejmanowski A.Q., Dierksheide J.E., Williams J.W., Chong A.S., and Waldman W.J. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 71 1 (Jan 15 2001) 170-174
41. Evers D.L., Wang X., Huong S.M., Andreoni K.A., and Huang E.S. Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antivir Res 65 1 (Jan 2005) 1-12
42. Naesens L., and De Clercq E. Recent developments in herpes virus therapy. Herpes 8 1 (Mar 2001) 12-16